SCHEDULE: Deerfield Management Updates BiomX Ownership Stake

Deerfield Management reports a change in its percentage of beneficial ownership in BiomX Inc. due to an increase in the company's total outstanding shares.

Summary

• Deerfield Management and its affiliated funds report a combined beneficial ownership of 989,056 shares of BiomX Inc. common stock.
• The reported ownership represents 9.99% of the company's total outstanding common stock.
• The change in percentage ownership is solely attributed to the increase in the total number of outstanding shares of BiomX Inc. rather than any new trading activity.
• The total outstanding shares used for calculation is 8,766,516, reflecting recent issuances in April 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It confirms that a major institutional investor remains committed to the company despite recent share dilution.

Positives

• The reporting entities maintain a significant 9.99% stake, signaling continued institutional interest in the issuer.
• The filing confirms no recent divestment activity by the major shareholder over the past 60 days.

Negatives

• The dilution of the reporting person's percentage ownership is a direct result of the company issuing additional shares, which may impact existing shareholders.

Risks

• The conversion of Series X Preferred Stock and exercise of warrants are subject to a 9.99% Beneficial Ownership Limitation, which restricts the ability of the reporting person to increase their stake beyond this threshold.

Future Outlook

The filing does not provide forward-looking guidance regarding the company's operations, focusing instead on the disclosure of beneficial ownership changes.

Management Comments

• The reporting persons disclaim beneficial ownership of shares issuable upon conversion or exercise to the extent that such ownership would exceed the 9.99% Beneficial Ownership Limitation.

Industry Context

StockSavvy.ai notes that institutional investors like Deerfield often maintain significant stakes in biotech firms to support clinical development, and the recent share issuance suggests the company is actively raising capital to fund its pipeline.

Comparison to Industry Standards

• The 9.99% ownership cap is a standard provision in institutional investment agreements for small-cap biotech companies to avoid triggering change-of-control provisions or regulatory hurdles.

Stakeholder Impact

• Existing shareholders may experience dilution due to the recent issuance of over 2.2 million shares in April 2026.

Next Steps

• Continued monitoring of the company's share count and potential future filings by major shareholders.

Key Dates

Keywords

BiomX, Deerfield Management, Schedule 13D, Beneficial Ownership, Biotech, Equity Dilution